Navigation Links
Dengue Vaccine Initiative welcomes latest progress in vaccine development
Date:9/11/2012

WASHINGTON, D.C.September 11, 2012Today, The Dengue Vaccine Initiative (DVI) welcomed new clinical trial results that reveal progress in developing the first-ever dengue vaccine. In a publication in The Lancet, pharmaceutical company Sanofi Pasteur reported results from the first study conducted to evaluate the efficacy of any dengue vaccine candidate against clinical dengue disease in a population naturally exposed to dengue.

Dengue vaccine development efforts have been difficult because dengue is caused by four different related viruses, known as DENV 1, 2, 3 and 4. The results published in today's study found that Sanofi's vaccine candidate was effective against DENV 1, 3 and 4, but DENV 2 appeared to be resistant to vaccine in this trial. The vaccine candidate, called CYD-TDV, was tested on a group of 4,002 schoolchildren in Thailand, where dengue is known to be endemic.

"While there is still much work to be done, these clinical trials mark a decisive step forward in the development of a safe and effective vaccine," said Dr. Luiz da Silva, Director of the Dengue Vaccine Initiative. "We support the progress made by Sanofi Pasteur as well as efforts by other organizations to deliver a vaccine to populations in endemic countries."

There is no vaccine available to treat or prevent dengue fever. While vaccines have been under development since the 1940s, little progress had been made until recently. Reported dengue cases have increased from an annual average of fewer than 300,000 cases during the 1980s to nearly 1 million per annum from 2000 to 2005.The WHO estimates that there are 50 to 100 million dengue infections a year.

"This is a dramatic increase in dengue incidence rates, and yet it's very likely that the numbers still do not reflect the full scope of the problem," said Dr. Ciro de Quadros, Executive Vice President of the Sabin Vaccine Institute. "An exact number is difficult to determine due to a lack of accurate diagnostic testing and common misdiagnosis."

Dengue is the most common mosquito-borne viral disease, with more than 2.5 billion people at risk for the disease globally, resulting in an estimated 21,000 deaths per year. Dengue symptoms can range from mild, flu-like symptoms to severe circulatory failure, coma and death. Most outbreaks occur during the rainy season in endemic countries like Thailand and Brazil, when mosquito populations are high.

Currently, there are several dengue vaccines in various stages of development, with four candidates, including Sanofi Pasteur's, in clinical trial stages. The results of this first study, a phase IIb clinical trial, are not yet sufficient to prove or disprove efficacy of CYD-TDV. However, Sanofi has already begun phase III studies among 31,000 children in Asia and Latin America. These studies will provide further information, including pivotal efficacy results and additional safety data.

"In addition to saving lives and reducing illness, a dengue fever vaccine, once introduced, will have significant positive impacts on the global economy," added Dr. Orin Levine, Executive Director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. "The cost of dengue fever in the Americas alone is estimated to be $2.1 billion annually, and the burden of lost wages and productivity, along with the cost of healthcare, takes a great toll in endemic countries across the globe."


'/>"/>
Contact: Johanna Harvey
johanna.harvey@sabin.org
202-621-1691
Sabin Vaccine Institute
Source:Eurekalert

Related medicine news :

1. Dengue Fever a Major Cost Burden in Puerto Rico
2. RV144 vaccine efficacy increased against certain HIV viruses
3. Too Few Girls Get HPV Vaccine Against Cancer: CDC
4. Cancer turns off important immune cells, complicating experimental vaccine therapies
5. UTMB receives $1.2 million to provide HPV vaccine
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Kindergarten Vaccines Close to Target Levels: CDC
8. Dartmouth medical research closes in on new tuberculosis vaccine
9. Vaccine and autism debate masks real problem
10. NIH awards $7.8 million for innovative HIV vaccine approaches
11. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The event is ... Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 ... owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... MELVILLE, N.Y. , Feb. 5, 2016  Henry ... of health care products and services to office-based dental, ... has entered into an agreement to acquire a majority ... dental supplies and equipment in Brazil ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Obstetrics ... company profile to their offering. ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology: